# ESPLSM: An Efficient and Interpretable Mediation Analysis Framework Using Sparse Envelopes

**Authors:** Yeonhee Park, Zhihua Su

PMC · DOI: 10.1002/sim.70464 · 2026-03-18

## TL;DR

This paper introduces ESPLSM, a new method for mediation analysis that improves accuracy and interpretability in high-dimensional biomedical studies.

## Contribution

ESPLSM integrates sparse envelopes with mediation analysis to enhance estimation and interpretation of causal effects.

## Key findings

- ESPLSM outperforms existing methods in estimation accuracy and statistical power.
- The method provides new insights into molecular mechanisms of targeted cancer therapies.
- Theoretical guarantees for asymptotic efficiency and selection consistency are established.

## Abstract

Mediation analysis is a fundamental tool for understanding biological mechanisms through which an exposure exerts its effect on an outcome via intermediate variables, or mediators. However, modern biomedical studies often involve multiple exposures and mediators with complex correlation structures, and may also involve multiple outcomes, as in multi‐omics or imaging studies, where existing mediation analyses can suffer from instability and limited interpretability. In this work, we propose Envelope‐Based Sparse Partial Least Squares for Mediation Analysis (ESPLSM), which integrates dimension reduction and sparsity enforcement via the sparse envelope model to improve estimation and interpretation of causal effects. We embed the envelope model within the causal mediation framework based on potential outcomes, which allows us to formally define and identify direct and indirect effects and to establish theoretical guarantees, including asymptotic efficiency and selection consistency. Through simulation studies, we show that ESPLSM outperforms existing methods in terms of estimation accuracy, statistical power, and variable selection. Finally, we apply ESPLSM to a cancer cell line dataset to investigate the role of RNA expression in mediating the effect of EGFR mutations on drug responses. Our results provide new insights into the molecular mechanisms underlying targeted cancer therapies. Overall, ESPLSM provides a statistically principled yet practical solution for interpretable and efficient mediation analysis in modern high‐dimensional biomedical applications.

## Linked entities

- **Genes:** EGFR (epidermal growth factor receptor) [NCBI Gene 1956]
- **Diseases:** cancer (MONDO:0004992)

## Full-text entities

- **Genes:** EGFR (epidermal growth factor receptor) [NCBI Gene 1956] {aka ERBB, ERBB1, ERRP, HER1, NISBD2, NNCIS}
- **Diseases:** NSCLC (MESH:D002289), EPLSM (MESH:D019292), HIMA (MESH:D004195), Cancer (MESH:D009369)
- **Chemicals:** Osimertinib (MESH:C000596361), AZD8931 (MESH:C548875), AZD3759 (MESH:C000604577), AST.1306 (MESH:C568037), Gefitinib (MESH:D000077156), Tivozanib (MESH:C553176), Erlotinib (MESH:D000069347), PF.00299804 (MESH:C525726), CI.1033 (MESH:C420268), Cetuximab (MESH:D000068818), HIMA (-), Afatinib (MESH:D000077716), Pelitinib (MESH:C413879), Lapatinib (MESH:D000077341)
- **Species:** Homo sapiens (human, species) [taxon 9606]
- **Mutations:** T790M

## Figures

2 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12999549/full.md

---
Source: https://tomesphere.com/paper/PMC12999549